Dr. Ilyas Sahin is a medical oncologist based in Boston in the United States, serving at Massachusetts General Hospital, one of the world’s leading hospitals, and a faculty member (Assistant Professor) at Harvard Medical School.
In his clinical practice he focuses especially on liver, stomach, esophageal and pancreatic cancers, while his research covers all solid tumors (including lung, breast, prostate, colorectal and other cancers), working on next-generation cancer drugs and early-phase clinical trials.
A book answering the most-asked and most commonly misunderstood questions about cancer with scientific evidence.
The book and its answers are presented in Turkish.
Akdeniz diyeti kanseri önlemede etkili midir? (in Turkish)
D vitamini kansere karşı koruyucu mudur? (in Turkish)
Mikrodalga fırın kansere neden olur mu? (in Turkish)
“...Kanser değil kemoterapi öldürür...” iddiası doğru mu? Bilim karşıtlarının hedefi olan “kemoterapi, kanseri mi yoksa hastayı mı öldür?” sorusunun cevabı nedir? (in Turkish)
Günlük düşük doz aspirin kullanımı kanseri oluşumunu önler mi? (in Turkish)Plain-language summaries of studies published in peer-reviewed journals. Each summary links to the original article.
Original article: Mechanisms of drug resistance in HCC. Hepatology, 2024
A comprehensive review bringing together the mechanisms that cause treatments to lose their effectiveness over time in hepatocellular carcinoma, and the approaches being developed to overcome this resistance.
Open the original articleOriginal abstract: Clinical validation of Northstar Response, a novel methylated ctDNA therapy response monitoring assay. ASCO GI, 2024
Initial results of a new test that measures tumor-derived DNA fragments in the blood to monitor whether treatment is working in advanced gastrointestinal cancers.
Open the original abstractOriginal article: CRISPR in Targeted Therapy and Adoptive T Cell Immunotherapy for Hepatocellular Carcinoma. J Hepatocell Carcinoma, 2024
A review of how CRISPR technology could be used in targeted therapies and in treatments that use the patient’s own T cells.
Open the original articleShort notes and literature interpretations Dr. Sahin shares on X, translated into English. Each note includes the underlying source and a link to the original post.
Could AI help radiologists catch liver cancers that might otherwise be missed? An AI system that analyzes liver CT scans was tested prospectively in 10,333 consecutive patients. The system flagged 51 previously missed lesions, 15 of which were cancer. Ultimately 37 radiology reports were revised and 22 patients were referred for multidisciplinary evaluation. A single-center study whose findings still require radiologist confirmation, but a meaningful step toward real clinical use.
It was wonderful to discuss the opportunities and challenges in precision oncology on the #WINSympo2026 panel today. Thanks to the WIN Consortium for bringing together such a strong group!
A pooled analysis of 1,038 patients with operable melanoma who received treatment before surgery. Among the 735 patients who received immunotherapy, 58% had very little or no viable tumor left at the time of surgery. About 98% of these patients were alive at 5 years.
Interviews, television appearances, and conference talks.
Short videos with scientific answers to common questions and misconceptions about cancer.
What do the charts say: have cancer cases increased?Instagram · Turkish
Is it true that “people don’t die of cancer, they die of chemotherapy”?Instagram · Turkish
How true is the claim that “sugar feeds cancer”?Instagram · Turkish2.900+
citations, Google Scholar (October 2026)
